189 related articles for article (PubMed ID: 30275185)
1. Absence of HER2 Expression of Circulating Tumor Cells in Patients with Non-Metastatic Esophageal Cancer.
Woestemeier A; Ghadban T; Riethdorf S; Harms-Effenberger K; Konczalla L; Uzunoglu FG; Izbicki JR; Pantel K; Bockhorn M; Reeh M
Anticancer Res; 2018 Oct; 38(10):5665-5669. PubMed ID: 30275185
[TBL] [Abstract][Full Text] [Related]
2. Circulating Tumor Cells as a Biomarker for Preoperative Prognostic Staging in Patients With Esophageal Cancer.
Reeh M; Effenberger KE; Koenig AM; Riethdorf S; Eichstädt D; Vettorazzi E; Uzunoglu FG; Vashist YK; Izbicki JR; Pantel K; Bockhorn M
Ann Surg; 2015 Jun; 261(6):1124-30. PubMed ID: 25607767
[TBL] [Abstract][Full Text] [Related]
3. The Potential Clinical Implications of Circulating Tumor Cells and Circulating Tumor Microemboli in Gastric Cancer.
Abdallah EA; Braun AC; Flores BCTCP; Senda L; Urvanegia AC; Calsavara V; Fonseca de Jesus VH; Almeida MFA; Begnami MD; Coimbra FJF; da Costa WL; Nunes DN; Dias-Neto E; Chinen LTD
Oncologist; 2019 Sep; 24(9):e854-e863. PubMed ID: 30846515
[TBL] [Abstract][Full Text] [Related]
4. Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients.
Banys-Paluchowski M; Witzel I; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer EF; Aktas B; Kasimir-Bauer S; Pantel K; Fehm T; Müller V
Anticancer Res; 2017 Jun; 37(6):3117-3128. PubMed ID: 28551653
[TBL] [Abstract][Full Text] [Related]
5. Detection of Circulating Tumor Cells by Fluorescent Immunohistochemistry in Patients with Esophageal Squamous Cell Carcinoma: Potential Clinical Applications.
Li SP; Guan QL; Zhao D; Pei GJ; Su HX; Du LN; He JX; Liu ZC
Med Sci Monit; 2016 May; 22():1654-62. PubMed ID: 27184872
[TBL] [Abstract][Full Text] [Related]
6. Circulatory Tumor Cells in Esophageal Adenocarcinoma.
Gopalan V; Lam AK
Methods Mol Biol; 2018; 1756():177-186. PubMed ID: 29600370
[TBL] [Abstract][Full Text] [Related]
7. Monitoring disease progression and treatment efficacy with circulating tumor cells in esophageal squamous cell carcinoma: A case report.
Qiao YY; Lin KX; Zhang Z; Zhang DJ; Shi CH; Xiong M; Qu XH; Zhao XH
World J Gastroenterol; 2015 Jul; 21(25):7921-8. PubMed ID: 26167094
[TBL] [Abstract][Full Text] [Related]
8. Prospective Comparison of the Prognostic Relevance of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow of a Single Patient's Cohort With Esophageal Cancer.
Konczalla L; Ghadban T; Effenberger KE; Wöstemeier A; Riethdorf S; Uzunoglu FG; Izbicki JR; Pantel K; Bockhorn M; Reeh M
Ann Surg; 2021 Feb; 273(2):299-305. PubMed ID: 31188197
[TBL] [Abstract][Full Text] [Related]
9. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients.
Wallwiener M; Hartkopf AD; Riethdorf S; Nees J; Sprick MR; Schönfisch B; Taran FA; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A
BMC Cancer; 2015 May; 15():403. PubMed ID: 25972110
[TBL] [Abstract][Full Text] [Related]
10. Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients.
Zhang S; Li L; Wang T; Bian L; Hu H; Xu C; Liu B; Liu Y; Cristofanilli M; Jiang Z
BMC Cancer; 2016 Jul; 16():526. PubMed ID: 27456503
[TBL] [Abstract][Full Text] [Related]
11. HER2 expression on tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer.
Nanou A; Zeune LL; Bidard FC; Pierga JY; Terstappen LWMM
Breast Cancer Res; 2020 Aug; 22(1):86. PubMed ID: 32787900
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor.
Beije N; Onstenk W; Kraan J; Sieuwerts AM; Hamberg P; Dirix LY; Brouwer A; de Jongh FE; Jager A; Seynaeve CM; Van NM; Foekens JA; Martens JW; Sleijfer S
Neoplasia; 2016 Nov; 18(11):647-653. PubMed ID: 27764697
[TBL] [Abstract][Full Text] [Related]
13. The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial.
Jaeger BAS; Neugebauer J; Andergassen U; Melcher C; Schochter F; Mouarrawy D; Ziemendorff G; Clemens M; V Abel E; Heinrich G; Schueller K; Schneeweiss A; Fasching P; Beckmann MW; Scholz C; Friedl TWP; Friese K; Pantel K; Fehm T; Janni W; Rack B
PLoS One; 2017; 12(6):e0173593. PubMed ID: 28586395
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.
Aktas B; Kasimir-Bauer S; Müller V; Janni W; Fehm T; Wallwiener D; Pantel K; Tewes M;
BMC Cancer; 2016 Jul; 16():522. PubMed ID: 27456970
[TBL] [Abstract][Full Text] [Related]
15. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial.
Fehm T; Müller V; Aktas B; Janni W; Schneeweiss A; Stickeler E; Lattrich C; Löhberg CR; Solomayer E; Rack B; Riethdorf S; Klein C; Schindlbeck C; Brocker K; Kasimir-Bauer S; Wallwiener D; Pantel K
Breast Cancer Res Treat; 2010 Nov; 124(2):403-12. PubMed ID: 20859679
[TBL] [Abstract][Full Text] [Related]
16. [Value of serum human epithelial growth factor receptor 2 extracellular domain and circulating tumor cells in evaluating therapeutic response in advanced gastric cancer].
Li Y; Peng Z; Zhang X; Gong J; Shen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Nov; 20(11):1293-1299. PubMed ID: 29178102
[TBL] [Abstract][Full Text] [Related]
17. Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program.
Müller V; Banys-Paluchowski M; Friedl TWP; Fasching PA; Schneeweiss A; Hartkopf A; Wallwiener D; Rack B; Meier-Stiegen F; Huober J; Rübner M; Hoffmann O; Müller L; Janni W; Wimberger P; Jäger B; Pantel K; Riethdorf S; Harbeck N; Fehm T;
ESMO Open; 2021 Dec; 6(6):100299. PubMed ID: 34839105
[TBL] [Abstract][Full Text] [Related]
18. Clinical Significance of Circulating Tumor Cells in Peripheral Blood of Patients with Esophageal Squamous Cell Carcinoma.
Matsushita D; Uenosono Y; Arigami T; Yanagita S; Nishizono Y; Hagihara T; Hirata M; Haraguchi N; Arima H; Kijima Y; Kurahara H; Maemura K; Okumura H; Ishigami S; Natsugoe S
Ann Surg Oncol; 2015 Oct; 22(11):3674-80. PubMed ID: 25652049
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of HER2 expression in urothelial carcinoma cells as a biomarker for circulating tumor cells.
Nini A; Hoffmann MJ; Lampignano R; Große Siemer R; van Dalum G; Szarvas T; Cotarelo CL; Schulz WA; Niederacher D; Neubauer H; Stoecklein NH; Niegisch G
Cytometry B Clin Cytom; 2020 Jul; 98(4):355-367. PubMed ID: 32212383
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of circulating tumor cells in the response to trastuzumab for HER2-negative metastatic gastric cancer.
Matsushita D; Uenosono Y; Arigami T; Yanagita S; Okubo K; Kijima T; Miyazono F; Hamanoue M; Hokita S; Nakashima S; Ohtsuka T; Natsugoe S
Cancer Chemother Pharmacol; 2021 Jun; 87(6):789-797. PubMed ID: 33641065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
